Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kezar Life Sciences, Inc. (KZR)
|
Add to portfolio |
|
|
|
| Price: |
$15.32
| | Metrics |
| OS: |
72.7
|
M
| |
-36
|
% ROE
|
| Market cap: |
$1.11
|
B
| |
|
|
|
Net cash:
|
$28.1
|
M
| |
$0.39
|
per share
|
|
EV:
|
$1.09
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$683.0
|
k
| |
1589.4
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
($1.16)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, general and administrative | 71.2 | 54.7 | 43.0 | 37.3 | | | |
| Research and development | | | | | 18.1 | 6.5 | 7.4 |
| General and administrative | | | | | 6.6 | 2.3 | 1.6 |
| EBIT | 0.0 | 0.0 | 0.0 | 0.0 | -24.7 | -8.7 | -9.0 |
| Pre-tax income | -68.2 | -54.6 | -41.7 | -35.1 | -23.2 | -8.5 | -9.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -68.2 | -54.6 | -41.7 | -35.1 | -23.2 | -8.5 | -9.0 |
| |
| Diluted EPS | ($1.01) | ($1.04) | ($0.95) | ($1.84) | ($2.26) | ($14.21) | ($26.56) |
| Shares outstanding (diluted) | 67.4 | 52.8 | 44.0 | 19.1 | 10.3 | 0.6 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|